# Aripiprazole for the Augmentation of Antidepressant Therapy

> **NCT01429831** · PHASE4 · COMPLETED · sponsor: **Taiwan Otsuka Pharm. Co., Ltd** · enrollment: 300 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Aripiprazole

## Key facts

- **NCT ID:** NCT01429831
- **Lead sponsor:** Taiwan Otsuka Pharm. Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2014-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01429831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01429831, "Aripiprazole for the Augmentation of Antidepressant Therapy". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01429831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*